thalidomide has been researched along with Adenocarcinoma in 31 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study aimed to evaluate the effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in BALB/c female mice." | 8.12 | The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. ( Goleh, Z; Mokhtari-Dizaji, M; Toliyat, T, 2022) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 5.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies." | 5.32 | Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study aimed to evaluate the effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in BALB/c female mice." | 4.12 | The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. ( Goleh, Z; Mokhtari-Dizaji, M; Toliyat, T, 2022) |
| " Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications." | 3.76 | Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. ( Dalgleish, AG; Liu, WM; Nizar, S, 2010) |
| " The maximum tolerated dose (MTD) of lenalidomide given in combination with gemcitabine was defined as the highest dose level at which no more than one out of four (25%) subjects experiences a dose-limiting toxicity (DLT)." | 2.80 | A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. ( Liljefors, M; Rossmann, E; Ullenhag, GJ, 2015) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13." | 2.77 | Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. ( Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M, 2012) |
| "Lenalidomide has acceptable toxicity and is associated with long-term disease stabilization and PSA declines." | 2.75 | Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. ( Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M, 2010) |
| "Thalidomide was well tolerated and induced a median reduction in prostate-specific antigen of 41% without affecting testosterone." | 2.73 | Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. ( Do, KA; Efstathiou, E; Logothetis, CJ; McDonnell, TJ; Pettaway, CA; Pisters, LL; Troncoso, P; Wen, S, 2007) |
| "Thalidomide has been shown to inhibit the ability of tumors to recruit new blood vessels." | 2.70 | A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. ( Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J, 2001) |
| "Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer." | 1.46 | Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2. ( Agwa, H; El-Aarag, B; Kasai, T; Masuda, J; Seno, M; Zahran, M, 2017) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 1.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | 1.38 | Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib. ( Marschner, N; Zaiss, M, 2012) |
| "Thalidomide has been reported to have antiangiogenic and antimetastatic effects." | 1.33 | A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. ( Chen, CC; Lin, YC; Shun, CT; Wu, MS, 2006) |
| "Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies." | 1.32 | Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003) |
| "In patients with metastatic prostate cancer, we are evaluating the addition of the bisphosphonate alendronate when added to ketoconazole for impact on matrix metalloproteinase (MMP)-2 and MMP-9 as well as traditional clinical endpoints." | 1.31 | National Cancer Institute intramural approach to advanced prostate cancer. ( Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.68) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Goleh, Z | 3 |
| Mokhtari-Dizaji, M | 3 |
| Toliyat, T | 3 |
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Ullenhag, GJ | 1 |
| Rossmann, E | 1 |
| Liljefors, M | 1 |
| El-Aarag, B | 1 |
| Kasai, T | 1 |
| Masuda, J | 1 |
| Agwa, H | 1 |
| Zahran, M | 1 |
| Seno, M | 1 |
| Zuo, W | 1 |
| Zhu, X | 1 |
| Yang, J | 1 |
| Mei, Z | 1 |
| Deng, M | 1 |
| Lin, Q | 1 |
| Song, Y | 1 |
| Yin, Q | 1 |
| Liu, Y | 2 |
| Li, H | 1 |
| Matsui, O | 1 |
| Liu, WM | 1 |
| Nizar, S | 1 |
| Dalgleish, AG | 2 |
| Ning, YM | 1 |
| Gulley, JL | 1 |
| Arlen, PM | 2 |
| Woo, S | 1 |
| Steinberg, SM | 1 |
| Wright, JJ | 1 |
| Parnes, HL | 1 |
| Trepel, JB | 1 |
| Lee, MJ | 1 |
| Kim, YS | 1 |
| Sun, H | 1 |
| Madan, RA | 1 |
| Latham, L | 1 |
| Jones, E | 1 |
| Chen, CC | 2 |
| Figg, WD | 4 |
| Dahut, WL | 2 |
| Ong, SJ | 1 |
| Teo, M | 1 |
| Lim, KH | 1 |
| Choo, SP | 1 |
| Toh, HC | 1 |
| Keizman, D | 2 |
| Zahurak, M | 2 |
| Sinibaldi, V | 1 |
| Carducci, M | 2 |
| Denmeade, S | 1 |
| Drake, C | 1 |
| Pili, R | 1 |
| Antonarakis, ES | 2 |
| Hudock, S | 1 |
| Eisenberger, M | 1 |
| Zabransky, DJ | 1 |
| Smith, HA | 1 |
| Thoburn, CJ | 1 |
| Eisenberger, MA | 1 |
| McNeel, DG | 1 |
| Drake, CG | 1 |
| Henry, JY | 1 |
| Lu, L | 1 |
| Adams, M | 1 |
| Meyer, B | 1 |
| Bartlett, JB | 1 |
| Galustian, C | 1 |
| Marschner, N | 1 |
| Zaiss, M | 1 |
| Brent, R | 1 |
| Fraser, C | 1 |
| Li, X | 1 |
| Liu, X | 1 |
| Wang, J | 1 |
| Wang, Z | 1 |
| Jiang, W | 1 |
| Reed, E | 1 |
| Zhang, Y | 1 |
| Li, QQ | 1 |
| Ng, SS | 1 |
| Gütschow, M | 1 |
| Weiss, M | 1 |
| Hauschildt, S | 1 |
| Teubert, U | 1 |
| Hecker, TK | 1 |
| Luzzio, FA | 1 |
| Kruger, EA | 2 |
| Eger, K | 1 |
| BACH, A | 1 |
| BICHEL, J | 1 |
| HEJGAARD, JJ | 1 |
| Gulley, J | 2 |
| Cox, MC | 1 |
| Linehan, WM | 1 |
| Dahut, W | 1 |
| Hada, M | 1 |
| Mathew, P | 1 |
| Logothetis, CJ | 2 |
| Dieringer, PY | 1 |
| Chen, I | 1 |
| Pagliaro, LC | 1 |
| Bekele, BN | 1 |
| Zhou, X | 1 |
| Daliani, DD | 1 |
| Lin, YC | 1 |
| Shun, CT | 1 |
| Wu, MS | 1 |
| Efstathiou, E | 1 |
| Troncoso, P | 1 |
| Wen, S | 1 |
| Do, KA | 1 |
| Pettaway, CA | 1 |
| Pisters, LL | 1 |
| McDonnell, TJ | 1 |
| Zhang, HG | 1 |
| Li, J | 1 |
| Qin, SK | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Pollard, M | 1 |
| Calder, K | 1 |
| Bruera, E | 1 |
| Arlen, P | 1 |
| Fernandez, P | 1 |
| Noone, M | 1 |
| Fedenko, K | 1 |
| Hamilton, M | 1 |
| Parker, C | 1 |
| Pluda, J | 1 |
| Tchekmedyian, NS | 1 |
| Napalkov, NP | 1 |
| Gershbein, LL | 1 |
| Roe, FJ | 1 |
| Walters, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer[NCT01547260] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Adenocarcinoma
| Article | Year |
|---|---|
[Transplacental carcinogenesis].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Abnormalities, Drug-Induced; Adenocarcinoma; Animals; Carcinogens; | 1977 |
9 trials available for thalidomide and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Mon | 2010 |
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progressi | 2010 |
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor | 2012 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Rin | 2006 |
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Cadherins; Cell Communication; Combined Modality Therapy; Epithelial Ce | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middl | 2001 |
21 other studies available for thalidomide and Adenocarcinoma
| Article | Year |
|---|---|
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2.
Topics: A549 Cells; Adenocarcinoma; Animals; Apoptosis; Cell Movement; Cell Survival; Female; Gene Expressio | 2017 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, | 2017 |
The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Female; Image Processing, Compu | 2009 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcita | 2010 |
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophag | 2010 |
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dis | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone | 2012 |
Correspondence.
Topics: Adenocarcinoma; Adolescent; Adult; Diethylstilbestrol; Female; Humans; Incidental Findings; Limb Def | 2012 |
Regarding how safe is "safe"?
Topics: Adenocarcinoma; Diethylstilbestrol; Female; Humans; Limb Deformities, Congenital; Pregnancy; Rubella | 2013 |
Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Base Sequence; Cell Line, Tumor; DNA, Complementary; Down-R | 2003 |
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Topics: Adenocarcinoma; Androgens; Angiogenesis Inhibitors; Animals; Aorta; Cell Division; Drug Screening As | 2003 |
STUDIES ON THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE.
Topics: Adenocarcinoma; Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, | 1963 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topi | 2002 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; | 2004 |
A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Prolife | 2006 |
Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats.
Topics: Adenocarcinoma; Animals; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Male; Neopl | 1996 |
Thalidomide for night sweats in patients with advanced cancer.
Topics: Adenocarcinoma; Cachexia; Colonic Neoplasms; Female; Humans; Hypnotics and Sedatives; Middle Aged; S | 2000 |
Thalidomide and irinotecan-associated diarrhea.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; | 2002 |
The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Azoxymethane; Body Weight; Carcinogens; Colon; Dimet | 1991 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |